Regulatory Signal: On March 30, 2026, the FDA published a proposed rule in the Federal Register (Docket No. FDA-2026-N-0001, Document 2026-06064) proposing to reclassify Mycobacterium tuberculosis (MTB) cell-mediated immunity tests from Class III (Premarket Approval) to Class II (Special Controls with Premarket Notification). If finalized, this represents one of the most significant regulatory pathway changes for TB diagnostic device manufacturers in over a decade.
What Is Being Reclassified — and Why It Matters
The FDA's proposed rule targets two specific device product codes currently sitting in the highest regulatory classification tier:
- Product Code NCD — Mycobacterium tuberculosis cell-mediated immunity tests
- Product Code OJN — Mycobacterium tuberculosis cell-mediated immune response enzyme-linked immunospot (ELISpot) tests
Both product codes are intended for use as an aid in the diagnosis of Mycobacterium tuberculosis (TB) infection. Under the current framework, these are postamendments Class III devices requiring Premarket Approval (PMA) — the most burdensome and expensive regulatory pathway in the medical device industry.
The FDA is proposing to move both product codes into Class II (Special Controls), subject to Premarket Notification (510(k)). This is not a trivial administrative move. It changes the fundamental regulatory obligations for every manufacturer, importer, and distributor operating in this space.
The practical headline: If you make, plan to make, or distribute TB cell-mediated immunity tests, your regulatory strategy just changed — or is about to.
Understanding the Regulatory Framework: Class III vs. Class II
To appreciate why this proposal matters, it helps to understand what's actually changing at the regulatory pathway level.
| Feature | Class III (Current) | Class II (Proposed) |
|---|---|---|
| Regulatory Pathway | Premarket Approval (PMA) | Premarket Notification (510(k)) |
| Evidentiary Standard | Reasonable assurance of safety & effectiveness via clinical data | Substantial equivalence to a predicate device |
| FDA Review Time (Average) | 180 days (often 12–24+ months in practice) | 90 days (median ~177 days for De Novo; ~130 days for 510(k)) |
| Cost to Bring to Market | $75M–$100M+ (including clinical trials) | $31M average for 510(k), significantly lower than PMA |
| Post-Approval Requirements | PMA supplements for most changes | Special Controls + standard QSR/QMSR obligations |
| Annual Reporting | PMA Annual Report required | MDR, registration, and listing |
| Special Controls | N/A | Yes — FDA will establish specific performance criteria |
Citation Hook: The FDA's reclassification from Class III PMA to Class II 510(k) reduces average regulatory review burden by an estimated 30–50% in time-to-market and eliminates the need for independent pivotal clinical trial programs that can cost tens of millions of dollars.
This is a meaningful change for manufacturers. For startups and smaller diagnostics companies in particular, the difference between a PMA and a 510(k) pathway can be existential.
What Are Mycobacterium Tuberculosis Cell-Mediated Immunity Tests?
Tuberculosis remains one of the world's most pressing public health challenges. According to the World Health Organization (WHO), TB caused an estimated 1.25 million deaths in 2023, making it one of the leading infectious disease killers globally. In the United States, the CDC reported over 8,300 new TB cases in 2023, a number that continues to challenge public health infrastructure.
Cell-mediated immunity (CMI) tests for TB — most notably Interferon-Gamma Release Assays (IGRAs) and ELISpot-based tests — are critical tools in the TB diagnostic armamentarium. They detect the immune system's T-cell response to Mycobacterium tuberculosis antigens, offering advantages over the traditional tuberculin skin test (TST), including:
- Higher specificity — especially in BCG-vaccinated populations
- Single-visit testing — no return visit required to read results
- No cross-reactivity with BCG vaccination or most non-tuberculous mycobacteria (NTM)
The two product codes covered by this rulemaking represent the QuantiFERON-TB Gold platform (NCD) and T-SPOT.TB and similar ELISpot-based tests (OJN) — technologies that have been widely used in clinical practice for years despite their Class III classification.
The Lesson for Device Manufacturers: Reclassification Is an Opportunity — If You Prepare
Here is the practical takeaway I give every device manufacturer I work with at Certify Consulting: regulatory reclassification proposals are not just administrative news — they are strategic windows. The window opens when the proposed rule publishes. It closes when the final rule takes effect. What you do between those two dates determines whether you gain market advantage or scramble to catch up.
What Changes Under the Proposed Rule
-
New devices in the NCD and OJN categories would no longer require a PMA. They would enter the market via a 510(k), referencing a cleared predicate device.
-
Special Controls will be established by FDA to replace the PMA safety and effectiveness standard. Manufacturers must meet these special controls to clear a 510(k). The specific language of those controls is not yet final — and commenting on the proposed rule is your opportunity to influence them.
-
Existing PMA holders should monitor FDA guidance on transition provisions. Typically, when a device is reclassified down from Class III, existing PMA holders are notified and may be required to transition to the new regulatory framework or may be permitted to continue under their PMA until further action.
-
Product labeling and intended use must remain consistent with the cleared indication — aid in diagnosis of M. tuberculosis infection. Any expansion beyond that scope will trigger a new submission.
Specific Compliance Obligations: What You Need to Do Now
Whether you are a current PMA holder, a 510(k) applicant in planning, or a startup developing a new TB diagnostic, here is the compliance roadmap as I see it:
Step 1: Identify Your Product Code Exposure
Confirm whether your device is classified under NCD or OJN by reviewing your FDA 510(k)/PMA filing history or your device registration in the FDA's CDRH Product Code Database. If you are unsure, this is a foundational gap that needs to be resolved before the rule is finalized.
Step 2: Submit Comments During the Public Comment Period
The Federal Register notice opens a public comment window. FDA typically allows 60–90 days for comments on proposed rules of this nature. Use this window to:
- Advocate for achievable special controls language
- Flag performance standard metrics that may be technically infeasible
- Request clarity on transition timelines for existing PMA holders
- Raise questions about substantial equivalence predicates
This is not optional advocacy — it is strategic regulatory engagement. The special controls FDA establishes in the final rule will govern your product for years.
Step 3: Begin 510(k) Predicate Research
Even before the final rule is published, begin researching cleared predicates in the NCD and OJN product code space. Identify:
- Which devices FDA has previously cleared
- What performance data was submitted
- What labeling frameworks were accepted
This pre-work can shave 6–12 months off your 510(k) preparation timeline once the rule is finalized.
Step 4: Audit Your Quality Management System (QMS)
Class II devices under 21 CFR Part 820 (and the updated Quality Management System Regulation, or QMSR, now aligned with ISO 13485:2016) require a fully implemented QMS. If your organization has been operating under a PMA framework, your QMS may need recalibration to address:
- Design controls (21 CFR 820.30 / QMSR equivalent)
- Corrective and preventive action (CAPA)
- MDR reporting obligations specific to IVD diagnostics
Citation Hook: Under FDA's Quality Management System Regulation (QMSR), effective February 2, 2026, all Class II medical device manufacturers must maintain a QMS that substantially conforms to ISO 13485:2016 — a critical compliance threshold for any device entering the market via 510(k) after reclassification.
Step 5: Review Labeling for Special Controls Alignment
Once FDA publishes the final rule with specific special controls, your product labeling — including indications for use, performance claims, and limitations statements — must be reviewed against those controls. Noncompliant labeling is one of the most common 510(k) deficiency triggers in IVD submissions.
Effective Dates and Key Regulatory Milestones
| Milestone | Date / Timeline |
|---|---|
| Proposed Rule Published | March 30, 2026 |
| Public Comment Period Closes | Typically 60–90 days after publication (est. May–June 2026) |
| Final Rule Expected | 12–24 months post-comment closure (est. 2027) |
| Transition Period for Existing PMAs | To be determined by final rule |
| 510(k) Submissions Accepted for NCD/OJN | Upon effective date of final rule |
Note: These timelines are estimates based on typical FDA rulemaking cadence. Monitor the Federal Register and FDA CDRH announcements for official updates.
Why the FDA Is Doing This: The Regulatory Logic
FDA's rationale for reclassifying these devices rests on a well-established principle under 21 U.S.C. § 513(e): if general controls and special controls are sufficient to provide reasonable assurance of safety and effectiveness, Class III classification is no longer warranted.
For TB CMI tests, the agency's position is supported by:
- Decades of post-market performance data — IGRAs and ELISpot tests have extensive real-world use records with well-characterized performance profiles.
- Established clinical consensus — CDC, IDSA, and WHO guidelines all incorporate these tests into standard TB diagnostic algorithms, reflecting broad clinical validation.
- Predicate device landscape — The existence of cleared and approved devices provides a robust substantial equivalence framework for future submissions.
- International alignment — CE-marked equivalents under the EU IVDR have established performance benchmarks that FDA can reference in developing special controls.
Citation Hook: FDA's authority to reclassify postamendments Class III devices into Class II is grounded in Section 513(e) of the Federal Food, Drug, and Cosmetic Act, which permits downward reclassification when special controls are determined sufficient to ensure device safety and effectiveness without the full PMA evidentiary burden.
The net effect is a more proportionate regulatory burden — one that reflects the current state of science rather than the precautionary posture appropriate when these technologies first emerged.
What This Means for the Broader TB Diagnostics Market
This reclassification proposal has ripple effects beyond just NCD and OJN product holders. Consider the downstream implications:
- Increased market competition — A lower barrier to entry (510(k) vs. PMA) will likely attract new entrants to the TB diagnostics market, including companies offering novel platforms or point-of-care formats.
- Faster innovation cycles — Manufacturers can iterate on existing cleared devices more quickly under 510(k) supplemental pathways than PMA supplements.
- Global harmonization pressure — U.S. alignment with international regulatory approaches may ease dual-track regulatory strategies for manufacturers seeking both FDA clearance and CE marking.
- Pricing dynamics — Increased competition and lower development costs could exert downward pressure on pricing for healthcare systems and public health programs.
For companies already in this space, the strategic imperative is clear: act now to prepare your 510(k) framework so you are positioned to clear quickly once the final rule takes effect, rather than reacting after competitors have already filed.
How Certify Consulting Helps TB Diagnostic Device Manufacturers
At Certify Consulting, I've guided more than 200 FDA-regulated clients through regulatory transitions — including reclassifications, De Novo pathways, and 510(k) submissions for IVD devices. Our track record of 100% first-time audit pass rates reflects a disciplined, evidence-based approach to regulatory strategy.
For manufacturers affected by this proposed reclassification, I offer:
- Regulatory impact assessments — Mapping your current product portfolio against the proposed rule and identifying gaps
- 510(k) strategy development — Predicate selection, substantial equivalence arguments, and performance testing protocols
- QMS gap analysis — Benchmarking your current QMS against QMSR/ISO 13485:2016 requirements
- FDA comment drafting — Strategic, technically grounded comments to shape special controls language in your favor
- Submission preparation — End-to-end 510(k) preparation once the final rule is effective
If you're navigating this reclassification and want expert guidance tailored to your device portfolio, contact Certify Consulting to schedule a regulatory strategy session.
You may also find our detailed guidance on 510(k) submission preparation for IVD devices valuable as you begin planning your pathway.
FAQ: FDA Reclassification of TB Cell-Mediated Immunity Tests
Does this reclassification affect currently marketed TB tests?
Yes. Existing PMA holders for NCD and OJN devices will need to monitor FDA's transition provisions in the final rule. FDA typically provides a pathway for existing PMA holders to convert to or operate alongside the new 510(k) framework.
When will the final rule take effect?
The proposed rule was published March 30, 2026. Based on typical FDA rulemaking timelines, a final rule could be expected in 2027, though this is not guaranteed. Manufacturers should monitor the Federal Register and FDA CDRH for updates.
What are "special controls" and how will they affect my device?
Special controls are FDA-established requirements — such as performance standards, labeling requirements, or post-market surveillance obligations — that substitute for the full PMA evidentiary standard. For NCD and OJN devices, these will likely include minimum sensitivity/specificity thresholds, labeling requirements for intended use, and potentially post-market study commitments. The exact language is still being developed.
Can I submit a 510(k) for a TB CMI test right now?
Not under the standard 510(k) pathway — these are currently Class III devices. However, a De Novo request may be an available pathway if you believe your device is novel with low-to-moderate risk. Once the reclassification final rule is effective, standard 510(k) submissions will be accepted.
What is the difference between NCD and OJN product codes?
NCD covers general MTB cell-mediated immunity tests (primarily IGRA-based, such as QuantiFERON platforms), while OJN specifically covers MTB cell-mediated immune response enzyme-linked immunospot (ELISpot) tests (such as T-SPOT.TB). Both are proposed for reclassification under the same rule but may have different special controls in the final rule.
Last updated: 2026-04-04
Jared Clark is a GMP and FDA regulatory compliance consultant at Certify Consulting, serving 200+ clients across FDA-regulated industries with a 100% first-time audit pass rate. Learn more at certify.consulting.
Jared Clark
GMP Compliance Consultant, Certify Consulting
Jared Clark is a GMP compliance consultant and founder of Certify Consulting, specializing in FDA GMP requirements for pharmaceuticals, dietary supplements, cosmetics, and food manufacturing.